Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Interest Expenses (2016 - 2023)

RedHill Biopharma has reported Interest Expenses over the past 12 years, most recently at $1.9 million for Q2 2023.

  • Quarterly Interest Expenses fell 54.3% to $1.9 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2024, down 60.11% year-over-year, with the annual reading at $1.5 million for FY2025, 3.7% down from the prior year.
  • Interest Expenses was $1.9 million for Q2 2023 at RedHill Biopharma, up from $421000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $31.8 million in Q3 2022 and troughed at $74000.0 in Q2 2019.
  • The 5-year median for Interest Expenses is $3.7 million (2020), against an average of $4.2 million.
  • Year-over-year, Interest Expenses tumbled 95.69% in 2019 and then surged 4839.19% in 2020.
  • A 5-year view of Interest Expenses shows it stood at $187000.0 in 2019, then surged by 2335.29% to $4.6 million in 2020, then dropped by 19.06% to $3.7 million in 2021, then crashed by 32.69% to $2.5 million in 2022, then decreased by 22.37% to $1.9 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Interest Expenses are $1.9 million (Q2 2023), $421000.0 (Q1 2023), and $2.5 million (Q4 2022).